Acquisitions - Purchase Price Allocation (Details) - USD ($)	3 Months Ended	6 Months Ended		14 Months Ended
	Jun. 30, 2023	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Dec. 31, 2022	Apr. 18, 2022
Purchase price allocation:
Goodwill	$ 3,873,079	$ 3,873,079		$ 3,873,079	$ 3,301,959
Measurement period adjustments - goodwill		(571,120)
Measurement period adjustment - deferred tax liability		$ 571,120	$ 3,326,000
Elusys Therapeutics
Purchase price allocation:
Cash and cash equivalents						$ 5,719,899
Contract receivables						24,526,232
Prepaid expenses and other current assets						1,818,278
Inventory						5,844,000
Intangible asset - definite-lived (Note 7)						9,700,000
Property and equipment						50,224
Operating lease right of use assets						352,906
Other assets						1,329,153
Total assets acquired						49,340,692
Accounts payable						(204,794)
Accrued expenses and other current liabilities						(5,155,363)
Operating lease obligations						(352,906)
Deferred income tax liability						(3,644,120)
Other liabilities						(1,002,904)
Total liabilities assumed						(10,360,087)
Net assets acquired and liabilities assumed						38,980,605
Goodwill						3,873,080
Total purchase consideration						$ 42,853,685
Total revenue of acquiree from acquisition date				30,000.00
Net loss of acquiree from acquisition date				$ 1,200,000
Measurement period adjustment - deferred tax liability	$ (600,000)